Radiopharmaceutical developer Navidea Biopharmaceuticals and Siemens Healthcare subsidiary PETNet Solutions have signed a radiopharmaceutical manufacturing agreement.
The deal covers Navidea's fluorine-18-labeled NAV4694 product, an investigational beta-amyloid PET imaging agent, Navidea said. Under the terms of the agreement, PETNet Solutions will manufacture NAV4694 clinical trial material at select U.S. radiopharmacies, with the possibility of expanding into additional PETNet locations next year, according to the firm.
NAV4694 is currently in phase II and III clinical trials in subjects who have signs or symptoms of cognitive impairment such as Alzheimer's disease, Navidea said.
